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Abstract  
Background: Hepatitis B virus (HBV) genotype C is associated with the development of hepatocellular carcinoma 
(HCC). In addition, HBV subgenotype C1 is the major subgenotype in Southern China. The aim of this study was to 
investigate whether there were the specific mutation patterns in HBV/C1 associated with Southern Chinese patients with 
HCC. 
Methods: Mutations in HBV basal core promoter (BCP) and their association with HCC were assessed in a matched 
cross-sectional control study of 102 HCC and 105 chronic hepatitis (CH) patients (from Guangdong, China) infected 
with HBV/C1. Functional analysis of HBx mutants was performed by the colony formation assay and the luciferase 
assays. 
Results: T1762/A1764 double mutations was frequently found in patients infected with HBV/C1, regardless of clinical 
status (64.7% in HCC and 51.4% in CH, P>0.05). Unexpectedly, the adjacent V1753 or A1768 mutation significantly 
increased the risk of HCC (P<0.05). Moreover, the prevalence of triple or quadruple mutations in BCP was significantly 
higher in patients with HCC than those with CH, particularly for HBeAg-positive-carriers (P<0.05). Functional analysis 
revealed that T1762/A1764 mutation alone did not alter the transcriptional activity and the inhibitory effects on cell 
proliferation of HBx, but triple or quadruple mutations largely abrogated this effect. 
Conclusions: Accumulation of mutations involving V1753 or/and A1768 in addition to T1762/A1764 in BCP region 
were closely related to HCC among the patients infected with HBV/C1, particularly for HBeAg-positive-carriers. The 
increased risk of HCC caused by BCP variants may be attributable partially to modifying the biological functions of 
HBx. 
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Introduction   
Hepatocellular carcinoma (HCC) is the fifth 
most frequent cancer and the third leading cause 
of cancer-related death in the world [1]. It is 
accepted that chronic infection with Hepatitis B 
virus (HBV) is a major risk factor for the 
development of HCC [2]. The HBV genome 
consists of a partially double-stranded circular 
DNA molecule comprising 3200 nucleotides, 
and exhibits considerable genetic variability 
because the polymerase lacks a proofreading 
function. At present, HBV is classified into 
eight genotypes (A to H) according to a 
divergence in the entire nucleotide sequence 
greater than 8% [3]. HBV genotypes have 
distinct geographical distributions and correlate 
with the severity of liver disease [3,4]. 
Genotypes B and C are prevalent in Asia, and 
genotype C is associated with a more severe 
course of liver disease and a higher risk of HCC 
development than genotype B [5,6]. 
Furthermore, subgenotypes have been identified 
in different HBV genotypes based on a 
divergence greater than 4% but less than 8% in 
the complete nucleotide sequence. There are 
two subgenotypes of genotype B with distinct 
geographical distributions, provisionally 
designated B1 (Bj, Japan) and B2 (Ba, other 
Asian countries) [7]. Clinical differences 
between the patients infected with HBV/Ba and 
HBV/Bj have been demonstrated, indicating a 
comparatively better prognosis of 
HBV/Bj-infection in comparison to HBV/Ba 
[8,9]. Recently, HBV/C has been classified into 
four subgenotypes (HBV/C1-C4) [10,11]. The 
two most widely spread subgenotypes are 
HBV/C1 (Cs), for Southeast Asia, and HBV/C2 
(Ce), for East Asia; they not only have different 
geographic distributions but also different 
clinical outcomes are becoming clear [12,13]. 
   The HBV core promoter (CP) resides in the 
overlapping X gene and plays a central role in 
HBV replication and morphogenesis [14]. Core 
promoter is composed of the core upstream 
regulatory sequence (CURS) and the basal core 
promoter (BCP). Mutations in BCP region at 
nucleotides (nt) 1762 and 1764 (T1762/A1764) 
were previously reported in association with 
HBe antigen seroconversion and viral 
replication. They were often found in the 
patients with advanced liver disease and HCC 
[15-19]. Recently, T1653 mutation in the box α 
of CURS and V1753 mutation in BCP region 
has also been reported to increase the risk of 
HCC in HBeAg-negative patients infected with 
HBV/C [20, 21]. As well, specific mutations in 
CP region of HBV were differently associated 
with HCC in the context of HBeAg status 
among HBV/C1 and HBV/C2 carriers [22]. 
However, the mechanism underlying CP 
mutation and hepatocarcinogenesis is largely 
unknown. 
As a highly endemic area for HBV infection, 
the prevalence of chronic HBV infection in 
China is between 8 and 20% of the general 
population, with an estimated 120 million 
hepatitis B surface antigen (HBsAg) carriers. 
The prevalence of HBV is uneven in different 
regions of China: high in some southern 
provinces (>8%) and low in some western 
provinces (4–6%) [23]. Genotypes B and C 
were identified as the most common HBV 
strains and account for approximately 95% of 
Chinese patients. Further study confirmed all 
genotype B strains belong to subgenotype Ba. 
Two of genotype C subgenotypes, C1 and C2, 
were found in China and they showed different 
geographic distributions. HBV/C1 was the 
major subgenotype in Southern China and C2 
was predominant in Northern China [23-26]. 
Previous reports indicated a significantly higher 
incidence of HCC in Southern China [27,28]. 
However, it is unclear whether there are the 
specific mutation patterns in CP of HBV 
responsible for the development of HCC in 
Southern China.  
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Objectives 
The aim of this study was to determine the 
HCC-associated mutations of the HBV genome 
in the entire CP and the overlapping X gene 
region in Southern Chinese patients infected 
with HBV/C1, and analyze the hotspot 
mutations through a cross-sectional control 
study. 
Materials and Methods 
Subjects 
A total of 209 serum samples were obtained from 
a cohort of patients with chronic hepatitis B, 
including 102 from chronic hepatitis (CH) 
patients and 102 from HCC patients, who had 
been recruited at the First affiliated Hospital of 
Guangzhou Medical College, Guangzhou China 
between June 2005 and December 2009. The 
diagnosis of HCC was made pathologically. All 
patients were chronic HBV C1 carriers, as 
identified by PCR-restriction fragment length 
polymorphism. None of the patients had 
co-infection with hepatitis C virus or other agents 
that are causes of liver disease. All serum samples 
were stored at -40°C until analysis. 
Amplification and sequencing of CP region of 
HBV   
HBV DNA was extracted from 100μl serum using 
a QIAamp DNA blood mini kit (QIAGEN GmbH, 
Hilden, Germany) according to the manufacturer’s 
instructions. In order to detect the genetic 
variations in CP region, HBV DNA sequence (nt. 
1176-1838) bearing the core promoter region and 
the overlapping X gene was amplified by PCR 
with hemi-nested primers. The first-round PCR 
was performed with the sense primer HBVF 
(1176-1195) and the antisense primer HBVR 
(1823-1804). The second-round PCR was 
performed with the sense primer HBVF 
(1266-1285) and the antisense primer HBVR 
(1823-1804) (Table 1). Amplified products were 
directly sequenced with Prism BigDye (Applied 
Biosystems, Foster City, CA) in the ABI 3100 
DNA automated sequencer. Sequences were 
compared using the Clustal W program. 
Table 1 Oligonucleotide primers used in the study  
Primer Sequence Position 
HBI   5′-TGCCAAGTGTTTGCTGACGC-3′ 1176–1195 
HB-R 5′-AAAGTTGCATGGTGCTGGTG-3′ 1823–1804 
HB2 5′-CCATACTGCGGAACTCCTAG-3′ 1266–1285 
HBVF1 5′-GAAAAGCTTCCACCATGGCTGCTAGGGTGTGCTG-3′ 1374–1393 
HBVR1 5′-CTAATCTCCTCCCCCAACTCCTCCCAGTC-3′ 1728–1756 
HBVF2-2 5′-GTTGGGGGAGGAGATTAGGTTAATGATCTTTGTAC-3′ 1739–1773 
HBVF2-3.1 5′-GTTGGGGGAGGAGAVTAGGTTAATGATCTTTGTAC-3′ 1739–1773 
HBVF2-3.2 5′-GTTGGGGGAGGAGATTAGGTTAATGATTTTTGTAC-3′ 1739–1773 
HBVF2-4 5′-GTTGGGGGAGGAGAVTAGGTTAATGATTTTTGTAC-3′ 1739–1773 
HBVR2 5′-CATCTCGAGTTAGGCAGAGGTGAAAAAGTTGCATG-3′ 1813–1838 
The underlined letters, restriction enzyme site (HindIII and XhoI); the solid letters, X gene mutant sites. 
Site-directed mutagenesis and plasmid 
construction   
The mutations in CP region were introduced by 
overlap extension PCR, by PCR-mediated 
site-directed mutagenesis with a set of designed 
mutagenetic primers (Table 1), as reported 
previously [29]. Briefly, single base changes were 
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introduced by PCR using internal primers 
containing the desired point mutation(s): 
HBVF2–2 (1739-1773), HBVF2–3.1 (1739-1773), 
HBVF2–3.2 (1739-1773) and HBVF2–4 
(1739-1773), paired with the outside primer 
HBV1883R2. Primer set HBVF1 
(1374-1393)/HBVR1 (1728-1756) was used to 
generate the products with the homologue ends 
overlapped with the above mutated fragments. 
The products of the first round PCR were purified 
and served as the templates for the second round 
PCR with the outside primer set 
HBVF1(1374-1393)/HBVR2(1813-1838) to 
generate a full-length HBx. The PCR products 
were cloned into the HindIII-XhoI sites of 
pcDNA3.1 (Invitrogen, Carlsbad, CA) to obtain 
the expression vectors of wild type or mutated 
HBx, respectively. All constructs were sequenced 
to confirm the desired sequences. 
The NF-κB luciferase reporter plasmids, 
NF-κB-Luc and mtNF-κB-Luc have been 
previously described [30]. NF-κB-Luc encodes 
consensus NF-κB sites upstream of a luciferase 
reporter; mtNF-κB-Luc is identical to NF-κB-Luc 
except that the NF-κB consensus sites are mutated 
so that NF-κB cannot bind and stimulate 
transcription.   
Cell culture and transfection   
HepG2 cells were maintained in Dulbecco’s 
modified Eagle’s medium (Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal bovine serum 
(Invitrogen) at 37 °C in a 5% CO2 environment. 
For transfection, cells were seeded in 96-well 
plates at 1.5×10
5
 cells/ml, grown to 50-80% 
confluency and transfected with the plasmids 
described above using Lipofectamine2000 
(Invitrogen) according to the manufacturer’s 
protocol. Following transfection, cells were 
incubated for 24 h before being harvested for the 
luciferase assay or gene expression assay.  
Western blot analysis 
Total cell lysates were prepared in RIPA buffer 
[50 mmol/L TrisHCl, pH 8.0, 150 mmol/L NaCl, 
1% (vol/vol) Nonidet P-40, 0.5% (wt/vol) 
sodium desoxycholate, 0.1% (wt/vol) SDS] 
containing the complete protease inhibitor 
cocktail. Western blot analysis was performed 
as described with the following primary 
antibodies: monoclonal mouse anti-HBx 
(Abcam, CA, USA) and mouse anti-β-actin 
(Sigma, MO, USA). Experiments were repeated 
in triplicate. 
Luciferase assays   
Transfected cells were harvested in Passive Lysis 
Buffer (Promega) and the cell lysates were 
analyzed for luciferase activity by the Dual 
Luciferase Reporter Assay System (Promega, CA 
USA) according to the manufacturer’s directions. 
Colony formation assay    
After cells were transfected for 48 h, they were 
transferred to a 60 mm plate and cultured in G418 
(Invitrogen) selective medium for 2 weeks (G418 
700 μg/ml). The cell culture medium was changed 
every 3 or 4 days until the colonies formed. 
Drug-resistant colonies were fixed with cold 
methanol, stained with Giemsa, and then scored. 
Statistical analysis 
Mutations between the two groups of samples 
were analyzed with relative risk test (OR value) 
and chi-square test (χ2 analysis). Statistical 
comparisons between other indexes were analyzed 
by Student’s t-test. Regression and correlation 
were done by Pearson method. A P-value of less 
than 0.05 was taken as statistically significant. 
Results  
Mutations in the core promoter of HBV/C1 in 
patients with HCC and CH 
In order to detect the genetic variations in CP 
region, DNA fragment from HBV nt 1176-1838 
was amplified by hemi-nested PCR. As expected, 
the most frequently occurring mutation in CP was 
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T1762/A1764, which could be found in 57.9% of 
all HBV isolates. However, there was no 
difference in the prevalence of T1762/A1764 
between patients with HCC and CH (64.7% vs. 
51.4%, P>0.05). Interestingly, the adjacent T1766 
and A1768 mutations in BCP were significantly 
higher for the HCC group than for the CH group 
(18.6% vs. 6.7% and 24.5% vs. 8.6%, P<0.05, 
respectively) (Table 2). 
Table 2 Prevalence of mutations in the core promoter region between HCC and CH patients infected with HBV/C1 
Mutation Total (n=207) HCC (n=102) CH (n=105) P value OR (95% CI) 
T1653 
V1753 
T1762/A1764 
T1766 
A1768 
27 (13.0%) 
43 (29.5%) 
120 (57.9%) 
26 (25.5%) 
35 (16.9%) 
18 (17.6%) 
43 (42.1%) 
66 (64.7%) 
19 (18.6%) 
26 (24.5%) 
9 (8.5%) 
18 (17.1%) 
54 (51.4%) 
7 (6.7%) 
9 (8.6%) 
0.088 
0.034 
0.802 
0.044 
0.021 
… 
3.071 (1.68–5.86) 
… 
2.146 (0.96–7.12) 
2.869 (1.21–6.49) 
HCC, hepatocellular carcinoma; CH, chronic heptitis; OR, odds ratio; CI, confidence interval.*P<0.05 comparing the frequency of triple 
mutation or quadruple mutation in HCC vs.CH. 
Since T1653 and V1753 mutations have been reported to be more closely associated with the 
progression of liver disease from chronic hepatitis to cirrhosis and/or HCC, we also compared the 
prevalence of these two mutations between HCC and CH patients. The prevalence of T1653 was 
relatively lower, with 17.6% in HCC group and 8.5% in CH group, but no statistical difference was 
found in this study (P>0.05). However, the frequency of V1753 mutation was significantly higher in 
patients with HCC than those with CH (42.1% vs. 17.1%, P<0.05) (Table 2). 
The patterns of BCP mutation in patients infected with HBV/C1 are presented in Table 3. Single 
mutation was rare, which was only found in two cases for V1753. Interestingly, the prevalence of V1753 
or A1768 mutation always occurred along with T1762/A1764. Although previously reports that 
T1762/A1764 double mutation increased the risk of HCC
4-7
, no the correlation was observed between 
T1762/A1764 mutation and clinical diagnosis in this study. However, mutations at position 1762/1764 in 
addition to V1753 or A1768 exhibited a close association to HCC. The frequencies of 1753/1762/1764, 
1762/1764/1768, or 1753/1762/1764/1768 mutations were significantly higher in patients with HCC 
than those with CH (11.8% vs.3.8%, 6.9% vs. 2.9%, or 2.9% vs. 0.95%, P<0.05, respectively).  
Table 3 Mutation patterns of BCP in HBV isolated from patients infected with HBV/C1 
Type  Pattern HCC (n=102) 
 
 CH (n=105)  
 
P value 
 V1753    T1762    A1764    T1766   A1768 
Wild-type 
Single mutation 
Double mutation 
 
Triple mutation 
 
 
quadruple mutation 
  -      -       -       -      - 
  +       -       -       -      - 
  -       +        +        -       - 
  -      -       -        +        +     
  +      +        +        -         -  
  -       +        +        +        -  
  -       +        +        -        +   
  +       +        +        -        +   
  -       +        +        +        + 
10 (9.8%) 
 0 (0%) 
77 (75.5%) 
 7 (6.8%) 
25 (24.5%)* 
11 (10.8%) 
13 (12.7%)* 
 8 (7.8%)* 
 4 (3.9%) 
19 (18.1%)  
 2 (1.9%) 
58 (55.1%) 
 5 (4.7%)   
10 (9.5%)   
 8 (7.6%) 
 3 (2.9%) 
 1 (0.95%) 
 0 (0%) 
0.201 
 
0.843 
0.912 
0.028 
0.062 
0.027 
0.016 
 
HCC, hepatocellular carcinoma; CH, chronic heptitis; *P<0.05 comparing the frequency of triple mutation or quadruple mutation in HCC 
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vs.CH. 
Accumulation of BCP mutations and HBeAg 
status in patients with HCC and CH 
BCP mutations were reported to be able to 
down-regulate the expression of HBeAg in cell 
culture system
13
. We have compared the rates of 
accumulation of BCP mutations and HBeAg 
status in patients with HCC and CH (Table 4). 
Among HBeAg-positive patients, there was no 
difference in the rate of T1762/A1764 double 
mutation between HCC group and CH group 
(65.7% vs. 54.1%, P>0.05). However, the rates of 
accumulative BCP mutations, such as 
1753/1762/1764, 1762/1764/1768, or 
1753/1762/1764/1768 mutations were 
significantly higher for the HCC group than for 
the CH group (14.3% vs.4.1%, 8.6% vs. 2.7%, or 
4.3% vs. 1.4%, P<0.05, respectively). 
Table 4 Accumulation of BCP mutations among patients with HCC and CH in context of HBeAg 
Mutation  HBeAg-positive group HBeAg-negative group 
HCC (n=70)        CH (n=74) P value HCC (n=32)        CH (n=31) P value 
T1762/A1764  
V1753/ T1762/A1764 
T1762/A1764/ A1768 
V1753/ T1762/A1764/A1768 
 46 (65.7%)  
 10 (14.3%)* 
6 (8.6%)* 
3 (4.3%)*   
 40 (54.1%)  
3 (4.1%) 
2 (2.7%) 
1 (1.4%) 
 0.891   
 0.027 
 0.031 
 0.041 
 20 (62.5%)  
2 (6.3%) 
1 (3.1%) 
 0 (0%)   
 14 (45.2%)  
 1 (3.2%) 
1 (3.2%) 
0 (0%)   
0.634 
0.062 
0.961 
*HCC vs.CH, P < 0.05 (Yates corrected chi-square). Significant data are shown in bold. 
Effect of BCP mutations on transactivation 
activity of HBx 
V1753, T1762, A1764 and A1768 mutation in 
BCP result in four amino acid (aa) substitutions 
change in HBx, i.e., aa 127 (Isoleucine to 
asparagine/serine/threonine), 130 
(lysine-to-methionine), 131 (valine-to-isoleucine) 
and 132 (phenylalanine-to-tyrosineat). T1766 
mutation does not cause aa change (Figure 1). In 
order to define the biological impact of BCP 
mutations on HBx, we introduced a series of 
artificial mutants into a wild type HBx template. 
pcDNA3.1-Xwt and pcDNA3.1-Xmt-2, 
pcDNA3.1-Xmt-3.1, pcDNA3.1-Xmt-3.2 and 
pcDNA3.1-Xmt-4 were constructed to express 
wild type HBx and HBx mutants. Transfection 
elliency was monitored by comparing the relative 
amount of cellular X protein using Western blot 
analysis (Figure 2C). To monitor the 
transactivation activity of different HBx 
constructs, a luciferase assay using the reporter 
construct of NF-κB-Luc or mtNF-κB-Luc was 
performed. HepG2 cells were transiently 
cotransfected with HBx and NF-κB-Luc or 
mtNF-κB-Luc plasmids. Like the wild type HBx, 
1762/1764 double mutation induced a 4-5-fold 
increase in luciferase activity, but 
1753/1762/1764, 1762/1764/1768 or 
1753/1762/1764/1768 mutations revealed largely 
inhibition of transactivation activity (Figure 2A). 
In contrast, we found that none of HBx constructs 
could activate mtNF-κB-Luc (Figure 2B). This 
result indicated that accumulative BCP mutations 
could inhibite the transcriptional activity of HBx.
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Figure 1 T1753V, A1762T/G1764A and C1766T/T1768A mutations in the X region, including the basal core promoter region 
 
 
 
 
 
 
 
 
Figure 2 Transactivational activity of HBx mutants. Six cell lines, HepG2-pcDNA3.1 (pcDNA3.1), HepG2-Xwt (Xwt), 
HepG2-Xmt-2 (Xmt-2), HepG2-Xmt-3.1 (Xmt-3.1), HepG2-Xmt-3.2 (Xmt-3.2) and HepG2-Xmt-4 (Xmt-4), were tested. 
Xmt-2, Xmt-3.1, Xmt-3.2 and Xmt-4 expressed HBx mutants containing 1762/A1764 double mutant, V1753/A1764/T1762 or 
T1762/A1764/A1768 triple mutant and V1753/T1762/A1764/A1768 quadruple mutant, respectively, whereas Xwt expressed 
wild type HBx. HBx constructs and NF-κB-Luc (A) or mtNF-κB-Luc (B), and renilla luciferase reporter vector pRL-TK were 
cotransfected into HepG2 cells. The relative luciferase activities were calculated and shown relative to that of HepG2 cells 
transfected with empty vector pcDNA3.1, which was set to 100%. The data are representative of at least two independent 
experiments. *P<0.05; **P<0.01. The expression levels of X protein were measured by Western blot analysis (C). 
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Impact of BCP mutations on growth-suppressive 
effect of HBx 
Because HBx can induce cell apoptosis, we next 
investigated the proapoptotic ability of different HBx 
mutants, using a colony formation assay. HepG2 cells 
were transfected with the different HBx expression 
plasmids, and 2 weeks after G418 selection, the 
number of colonies was scored. As expected, the 
expression of HBx caused a substantial reduction 
(5-fold) in the number of colonies compared with the 
control cells transfected with the empty vector 
pcDNA3.1. A degree of colony formation inhibition 
similar to that of HBx was observed in 1762/1764 
double mutation. Strikingly, 1753/1762/1764, 
1762/1764/1768, or 1753/1762/1764/1768 mutations 
exhibited abrogation of the growth-suppressive effect 
(Figure 3). The result indicated that BCP mutations 
affected the growth-suppressive effect of HBx in an 
accumulative manner.  
 
 
 
 
 
Figure 3 Growth-suppressive effect of HBx mutants. HepG2 cells were transfected with the HBx artificial mutants constructed according to 
the naturally occurring mutation pattern of BCP. After G418 selection for 2 weeks, drug-resistant clones were stained and scored. The results 
show the mean of two independent transfections. *P<0.05; **P<0.01. 
Discussion 
The infection of HBV is a major factor 
contributing to the development of HCC in 
China and the mutation in HBx plays an 
important role in this process. However, the 
impact of BCP mutations on HBx activity was 
unclear. We characterized CP mutations based 
on the serum samples taken from patients 
infected with HBV/C1 from the Southern China 
(Guangdong province) with a higher prevalence 
of HCC. We showed that although the 
frequency of T1762/A1764 double mutation 
was high in HCC patients, but there was no 
difference compared with that of CH patients. 
In contrast, the adjacent V1753 or A1768 
mutation significantly increased the risk of 
HCC. Recently, a longitudinal study 
demonstrated that T1762/A1764 mutation could 
be detected 4-7 years prior to HCC in most 
cases, while T1766/A1768 mutation occurred 
only at or near the stage of HCC, suggesting 
T1766/A1768 may be a more valuable 
predictive marker for HCC [31]. Because 
several reports demonstrated that T1766/A1768 
mutation enhanced viral replication [29, 32], 
high viral load caused by this mutation might 
contribute to hepatocarcinogenesis. The V1753 
mutation had been reported was specifically 
associated with HBV C1 among Chinese HCC 
patients [33], particularly for HCC among 
HBeAg-positive-C1-carriers [22]. Our study 
also confirmed that the V1753 mutation 
increases the risk of HCC in Chinese 
Guangdong with HBV/C1.  
 Li WH. et al. American journals of Cancer Review 2013, 1:17-28 
 
Ivy Union Publishing | http: //www.ivyunion.org April 15, 2013 | Volume 1 | Issue 1  
Page 9 of 12 
  It is noteworthy that T1762/A1764 double 
mutation always accompanied with V1753 or 
A1768 point mutation. We found that the rates 
of V1753/T1762/A1764, T1762/A1764/A1768 
or V1753/T1762/A1764/A1768 mutations were 
significantly higher in HCC patients compared 
with that in CH patients. The accumulation of 
BCP mutations involving V1753 or/and A1768 
in addition to T1762/A1764 were closely 
related to HCC among the patients infected with 
HBV/C1, particularly for 
HBeAg-positive-carriers. Although 
T1762/A1764 mutation alone was not a 
triggering factors of HCC, T1762/A1764 with 
the additional V1753 or/and A1768 mutations 
in BCP region could be appreciably higher risk 
for hepatocarcinogenesis. Some in vitro study 
showed that the T1762/A1764 double mutation 
had no significant effect on replication capacity 
in comparison to the wild type [32]. However, 
all CP mutants bearing additional mutations in 
this region, i.e., mutations at the position of 
V1753/T1762/A1764, T1762/A1764/A1768 or 
V1753/T1762/A1764/A1768 exhibited to 
markedly enhance viral replication than the wild 
type [32,34], supporting a carcinogenetic 
potential of this mutations pattern. Thus, it is 
reasonable to think these mutations in BCP may 
play a synergistic role on enhancing HBV 
carcinogenesis. 
Another feature of our study is that we try to 
understand the hepatocarcinogenesis potential 
of BCP mutations through HBV X protein 
(HBx) function. HBx is a multi-functional viral 
protein. It can modulate gene transcription, 
apoptosis, cell cycle, cell responses to genotoxic 
stress, protein degradation, and numerous signal 
transduction pathways [35-37] and, as a result, 
has been shown to induce cell transformation 
leading to HCC in a select strain of transgenic 
mice [38]. Functional study revealed that the 
COOH-terminus of HBx plays a key role in 
regulating its transcriptional activity and cells 
proliferation [39]. Since V1753, T1762, A1764 
and A1768 mutations cause four amino acid 
(aa) substitutions changes at HBx 
COOH-terminus, i.e., 127(I-to-N/S/T), 
130(K-to-M), 131(V-to-I) and 132(P-to-T), it is 
of interest to test whether BCP mutations affect 
the biological activity of HBx. We introduced a 
series of artificial mutants into a wild type HBx 
and constracted different HBx mutants. 
Transfection efficiency was monitored by 
comparing the relative amount of HBx by 
Western blot analysis. First, we analyzed the 
transactivation activity of different HBx through 
a luciferase assays. HepG2 cells were 
transiently co-transfected with NF-κB-Luc or 
mtNF-κB-Luc and HBx, and luciferase activity 
were examined. Like wild type HBx, 
T1762/A1764 double mutation induced a 
4-5-fold increase in luciferase activity. This 
result indicated that T1762/A1764 double 
mutation alone did not impact the effect of HBx. 
However, the mutations at positions 
V1753/T1762/A1764, T1762/A1764/A1768 or 
V1753/T1762/A1764/A1768 largely inhibited 
the transactivation activity of HBx. In contrast, 
we found that none of HBx constructs could 
activate mtNF-κB-Luc. We suggest that the 
number of BCP variants may be involved in the 
transactivation function of HBx, and 
contributed to the development of HCC. 
However, the relationship between 
transcriptional activity and oncogenic potential 
of mutated HBx in hepatocarcinogenesis needs 
to be carefully analyzed in each mutation.  
  We next investigated the proapoptotic ability of 
different HBx by a colony formation assay. We 
noted that the transactivation function of HBx is 
generally linked to its proapoptotic function. As 
expected, the expression of HBx caused a 
substantial reduction (5-fold) in the number of 
colonies compared with the control cells 
transfected with pcDNA3.1. A degree of colony 
formation inhibition similar to that of HBx was 
observed in T1762/A1764 double mutation. 
Strikingly, V1753/T1762/A1764, 
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T1762/A1764/A1768 or 
V1753/T1762/A1764/A1768 mutations exhibited 
abrogation of the growth-suppressive effect. 
These data further confirmed a synergistic role of 
BCP mutations could affect the function of HBx. 
However, the true impact of BCP mutations on the 
regulation of the biological function of HBx needs 
to be further evaluated.  
Conclusions 
Accumulation of mutations involving V1753 
or/and A1768 in addition to T1762/A1764 in BCP 
region were closely related to HCC among the 
patients infected with HBV/C1, particularly for 
HBeAg-positive-carriers. The increased risk of 
HCC caused by BCP variants may be attributable 
partially to modifying the biological functions of 
HBx. 
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